Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression

Chronic kidney disease (CKD) represents a global health epidemic, with approximately one-third of affected individuals ultimately necessitating renal replacement therapy or transplantation. The kidney, characterized by its exceptionally high energy demands, exhibits significant sensitivity to altera...

Full description

Saved in:
Bibliographic Details
Main Authors: Jinhu Chen, Qiuyuan Zhou, Lianjiu Su, Lihua Ni
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Renal Failure
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2506812
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850185181293445120
author Jinhu Chen
Qiuyuan Zhou
Lianjiu Su
Lihua Ni
author_facet Jinhu Chen
Qiuyuan Zhou
Lianjiu Su
Lihua Ni
author_sort Jinhu Chen
collection DOAJ
description Chronic kidney disease (CKD) represents a global health epidemic, with approximately one-third of affected individuals ultimately necessitating renal replacement therapy or transplantation. The kidney, characterized by its exceptionally high energy demands, exhibits significant sensitivity to alterations in energy supply and mitochondrial function. In CKD, a compromised capacity for mitochondrial ATP synthesis has been documented. As research advances, the multifaceted roles of mitochondria, extending beyond their traditional functions in oxygen sensing and energy production, are increasingly acknowledged. Empirical studies have demonstrated a strong association between mitochondrial dysfunction and the pathogenesis of fibrosis and cellular apoptosis in CKD. Targeting mitochondrial dysfunction holds substantial therapeutic promise, with emerging insights into its epigenetic regulation in CKD, particularly involving non-coding RNAs and DNA methylation. This article presents a comprehensive review of contemporary research on mitochondrial dysfunction in relation to the onset and progression of CKD. It elucidates the associated molecular mechanisms across various renal cell types and proposes novel research avenues for CKD treatment.
format Article
id doaj-art-5f2dd91884ca4b2a8567f6f9d60a62ce
institution OA Journals
issn 0886-022X
1525-6049
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Renal Failure
spelling doaj-art-5f2dd91884ca4b2a8567f6f9d60a62ce2025-08-20T02:16:49ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492025-12-0147110.1080/0886022X.2025.2506812Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progressionJinhu Chen0Qiuyuan Zhou1Lianjiu Su2Lihua Ni3Department of Nephrology, Huanggang Central Hospital of Yangtze University, Huanggang, ChinaDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaChronic kidney disease (CKD) represents a global health epidemic, with approximately one-third of affected individuals ultimately necessitating renal replacement therapy or transplantation. The kidney, characterized by its exceptionally high energy demands, exhibits significant sensitivity to alterations in energy supply and mitochondrial function. In CKD, a compromised capacity for mitochondrial ATP synthesis has been documented. As research advances, the multifaceted roles of mitochondria, extending beyond their traditional functions in oxygen sensing and energy production, are increasingly acknowledged. Empirical studies have demonstrated a strong association between mitochondrial dysfunction and the pathogenesis of fibrosis and cellular apoptosis in CKD. Targeting mitochondrial dysfunction holds substantial therapeutic promise, with emerging insights into its epigenetic regulation in CKD, particularly involving non-coding RNAs and DNA methylation. This article presents a comprehensive review of contemporary research on mitochondrial dysfunction in relation to the onset and progression of CKD. It elucidates the associated molecular mechanisms across various renal cell types and proposes novel research avenues for CKD treatment.https://www.tandfonline.com/doi/10.1080/0886022X.2025.2506812Chronic kidney diseasemitochondrial dysfunctioncell deathmitophagyoxidative stress
spellingShingle Jinhu Chen
Qiuyuan Zhou
Lianjiu Su
Lihua Ni
Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
Renal Failure
Chronic kidney disease
mitochondrial dysfunction
cell death
mitophagy
oxidative stress
title Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
title_full Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
title_fullStr Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
title_full_unstemmed Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
title_short Mitochondrial dysfunction: the hidden catalyst in chronic kidney disease progression
title_sort mitochondrial dysfunction the hidden catalyst in chronic kidney disease progression
topic Chronic kidney disease
mitochondrial dysfunction
cell death
mitophagy
oxidative stress
url https://www.tandfonline.com/doi/10.1080/0886022X.2025.2506812
work_keys_str_mv AT jinhuchen mitochondrialdysfunctionthehiddencatalystinchronickidneydiseaseprogression
AT qiuyuanzhou mitochondrialdysfunctionthehiddencatalystinchronickidneydiseaseprogression
AT lianjiusu mitochondrialdysfunctionthehiddencatalystinchronickidneydiseaseprogression
AT lihuani mitochondrialdysfunctionthehiddencatalystinchronickidneydiseaseprogression